Literature DB >> 32087150

Type 1 Interferon Responses Underlie Tumor-Selective Replication of Oncolytic Measles Virus.

Sarah Aref1, Anna Z Castleton1, Katharine Bailey1, Richard Burt1, Aditi Dey1, Daniel Leongamornlert2, Rachel J Mitchell1, Dina Okasha1, Adele K Fielding3.   

Abstract

The mechanism of tumor-selective replication of oncolytic measles virus (MV) is poorly understood. Using a stepwise model of cellular transformation, in which oncogenic hits were additively expressed in human bone marrow-derived mesenchymal stromal cells, we show that MV-induced oncolysis increased progressively with transformation. The type 1 interferon (IFN) response to MV infection was significantly reduced and delayed, in accordance with the level of transformation. Consistently, we observed delayed and reduced signal transducer and activator of transcription (STAT1) phosphorylation in the fully transformed cells. Pre-treatment with IFNβ restored resistance to MV-mediated oncolysis. Gene expression profiling to identify the genetic correlates of susceptibility to MV oncolysis revealed a dampened basal level of immune-related genes in the fully transformed cells compared to their normal counterparts. IFN-induced transmembrane protein 1 (IFITM1) was the foremost basally downregulated immune gene. Stable IFITM1 overexpression in MV-susceptible cells resulted in a 50% increase in cell viability and a significant reduction in viral replication at 24 h after MV infection. Overall, our data indicate that the basal reduction in functions of the type 1 IFN pathway is a major contributor to the oncolytic selectivity of MV. In particular, we have identified IFITM1 as a restriction factor for oncolytic MV, acting at early stages of infection.
Copyright © 2020 The American Society of Gene and Cell Therapy. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  IFITM1; ISG; MV; innate immune response; interferon-induced transmembrane protein 1; interferon-stimulated gene; measles virus; oncolytic measles virus; type 1 interferon

Mesh:

Substances:

Year:  2020        PMID: 32087150      PMCID: PMC7132605          DOI: 10.1016/j.ymthe.2020.01.027

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  41 in total

1.  The interferon-inducible RNA helicase, mda-5, is involved in measles virus-induced expression of antiviral cytokines.

Authors:  Heidi Berghäll; Jukka Sirén; Devanand Sarkar; Ilkka Julkunen; Paul B Fisher; Raija Vainionpää; Sampsa Matikainen
Journal:  Microbes Infect       Date:  2006-05-26       Impact factor: 2.700

2.  The Interferon-induced Transmembrane Proteins, IFITM1, IFITM2, and IFITM3 Inhibit Hepatitis C Virus Entry.

Authors:  Sumudu K Narayana; Karla J Helbig; Erin M McCartney; Nicholas S Eyre; Rowena A Bull; Auda Eltahla; Andrew R Lloyd; Michael R Beard
Journal:  J Biol Chem       Date:  2015-09-09       Impact factor: 5.157

3.  SLAM (CDw150) is a cellular receptor for measles virus.

Authors:  H Tatsuo; N Ono; K Tanaka; Y Yanagi
Journal:  Nature       Date:  2000-08-24       Impact factor: 49.962

4.  Constitutive Interferon Pathway Activation in Tumors as an Efficacy Determinant Following Oncolytic Virotherapy.

Authors:  Cheyne Kurokawa; Ianko D Iankov; S Keith Anderson; Ileana Aderca; Alexey A Leontovich; Matthew J Maurer; Ann L Oberg; Mark A Schroeder; Caterina Giannini; Suzanne M Greiner; Marc A Becker; E Aubrey Thompson; Paul Haluska; Mark E Jentoft; Ian F Parney; S John Weroha; Jin Jen; Jann N Sarkaria; Evanthia Galanis
Journal:  J Natl Cancer Inst       Date:  2018-10-01       Impact factor: 13.506

5.  ISG56 and IFITM1 proteins inhibit hepatitis C virus replication.

Authors:  Amit Raychoudhuri; Shubham Shrivastava; Robert Steele; Hangeun Kim; Ranjit Ray; Ratna B Ray
Journal:  J Virol       Date:  2011-10-05       Impact factor: 5.103

Review 6.  Interferon-stimulated genes: a complex web of host defenses.

Authors:  William M Schneider; Meike Dittmann Chevillotte; Charles M Rice
Journal:  Annu Rev Immunol       Date:  2014-02-06       Impact factor: 28.527

7.  Differential expression analysis for sequence count data.

Authors:  Simon Anders; Wolfgang Huber
Journal:  Genome Biol       Date:  2010-10-27       Impact factor: 13.583

8.  The IFITM proteins mediate cellular resistance to influenza A H1N1 virus, West Nile virus, and dengue virus.

Authors:  Abraham L Brass; I-Chueh Huang; Yair Benita; Sinu P John; Manoj N Krishnan; Eric M Feeley; Bethany J Ryan; Jessica L Weyer; Louise van der Weyden; Erol Fikrig; David J Adams; Ramnik J Xavier; Michael Farzan; Stephen J Elledge
Journal:  Cell       Date:  2009-12-24       Impact factor: 41.582

9.  IFITM1 is a tight junction protein that inhibits hepatitis C virus entry.

Authors:  Courtney Wilkins; Jessica Woodward; Daryl T-Y Lau; Amy Barnes; Michael Joyce; Nicola McFarlane; Jane A McKeating; D Lorne Tyrrell; Michael Gale
Journal:  Hepatology       Date:  2012-12-12       Impact factor: 17.425

10.  miRNA-36 inhibits KSHV, EBV, HSV-2 infection of cells via stifling expression of interferon induced transmembrane protein 1 (IFITM1).

Authors:  Hosni A M Hussein; Shaw M Akula
Journal:  Sci Rep       Date:  2017-12-21       Impact factor: 4.379

View more
  8 in total

1.  Peste des Petits Ruminants Virus Exhibits Cell-Dependent Interferon Active Response.

Authors:  Jingyu Tang; Aoxing Tang; Hanyu Du; Nannan Jia; Jie Zhu; Chuanfeng Li; Chunchun Meng; Guangqing Liu
Journal:  Front Cell Infect Microbiol       Date:  2022-05-31       Impact factor: 6.073

Review 2.  Opposing Roles of Type I Interferons in Cancer Immunity.

Authors:  Giselle M Boukhaled; Shane Harding; David G Brooks
Journal:  Annu Rev Pathol       Date:  2020-12-02       Impact factor: 23.472

Review 3.  Personalizing Oncolytic Virotherapy for Glioblastoma: In Search of Biomarkers for Response.

Authors:  Eftychia Stavrakaki; Clemens M F Dirven; Martine L M Lamfers
Journal:  Cancers (Basel)       Date:  2021-02-04       Impact factor: 6.639

Review 4.  Tackling HLA Deficiencies Head on with Oncolytic Viruses.

Authors:  Kerry Fisher; Ahmet Hazini; Leonard W Seymour
Journal:  Cancers (Basel)       Date:  2021-02-10       Impact factor: 6.639

Review 5.  Prospects for Using Expression Patterns of Paramyxovirus Receptors as Biomarkers for Oncolytic Virotherapy.

Authors:  Olga V Matveeva; Svetlana A Shabalina
Journal:  Cancers (Basel)       Date:  2020-12-05       Impact factor: 6.639

6.  Mesenchymal stromal cells equipped by IFNα empower T cells with potent anti-tumor immunity.

Authors:  Tao Zhang; Yu Wang; Qing Li; Liangyu Lin; Chunliang Xu; Yueqing Xue; Mingyuan Hu; Yufang Shi; Ying Wang
Journal:  Oncogene       Date:  2022-02-10       Impact factor: 8.756

7.  Identification of hub genes and their novel diagnostic and prognostic significance in pancreatic adenocarcinoma.

Authors:  Duo Zuo; Yongzi Chen; Xinwei Zhang; Zhuozhi Wang; Wenna Jiang; Fan Tang; Runfen Cheng; Yi Sun; Lu Sun; Li Ren; Rui Liu
Journal:  Cancer Biol Med       Date:  2021-08-17       Impact factor: 5.347

Review 8.  The gamble between oncolytic virus therapy and IFN.

Authors:  Qingbo Li; Fengxian Tan; Yuanyuan Wang; Xiaohui Liu; Xianbin Kong; Jingyan Meng; Long Yang; Shan Cen
Journal:  Front Immunol       Date:  2022-08-25       Impact factor: 8.786

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.